Shanghai Bio-heart Biological Technology (HKG:2185) obtained approval for Iberis Multi-Electrode Renal Artery Radiofrequency Ablation Catheter System from China's National Medical Products Administration for the treatment of hypertension patients, a Wednesday filing with the Hong Kong bourse said.
The system has been developed by unit Shanghai AngioCare Medical Technology, according to the interventional cardiovascular device company.